Pharmaceuticals News and Research

RSS

Achaogen announces completion of $56M Series C round of financing

Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was led by new investor Frazier Healthcare Ventures, and also included new investor Alta Partners.

7 Apr 2010

Illumina launches VeraCode ADME Core Panel

Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.

From Illumina, Inc. 7 Apr 2010

Gerresheimer AG sets up new sales office in Moscow

Gerresheimer AG has set up a sales office in Moscow. The new representation centre will intensify the Group's business in pharmaceutical primary packaging and drug-delivery systems. "This is a strategically important step to further develop the fast-growing pharma & healthcare markets of Russia and neighboring regions," says Gerresheimer CEO Dr. Axel Herberg.

7 Apr 2010

NNIT selects Verizon Business to manage global communications infrastructure for Novo Nordisk

NNIT, a leading Danish IT consultancy, has chosen Verizon Business to deploy and manage a global communications infrastructure for Novo Nordisk, the global health care company. A fully managed Verizon Private IP solution will provide secure, scalable and flexible connectivity for 75 of Novo Nordisk's locations around the world, helping the company to streamline its global operations, while also realizing cost and management efficiencies.

7 Apr 2010

Tigermed Consulting signs alliance agreement with ICON

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and Tigermed Consulting, a leader in the provision of clinical drug development services in China, today announced that they have signed an alliance agreement.

7 Apr 2010

TD2 to join GPEC at BayBio2010 to spur Arizona's bioscience industry

Scottsdale-based TGen Drug Development will join the Greater Phoenix Economic Council this week at BayBio2010 in an effort to spur Arizona's bioscience industry.

7 Apr 2010

Senator Grassley issues warning about 'phanton pharmacies' while Tampa officials arrest pharmacists on fraud charges

Senator Charles Grassley, R-Iowa, wrote a letter to Department of Health and Human Services Secretary Kathleen Sebelius this week saying federal officials have failed to stop the growing trend of "phantom pharmacies" that bill millions to Medicare in prescription drug costs then disappear, ABC News reports.

7 Apr 2010

Guidant imposed criminal penalty over $296M for withholding cardioverter defibrillator failure information

Guidant LLC pleaded guilty today in St. Paul, Minn., before U.S. District Court Judge Donovan W. Frank to criminal violations of the Federal Food, Drug and Cosmetic Act, the Justice Department announced. The medical device manufacturer's admission of criminal wrongdoing is the result of a four-year investigation into Guidant's handling of short-circuiting failures of three models of its implantable cardioverter defibrillators: the Ventak Prizm 2 DR (Model 1861) and the Contak Renewal (Models H135 and H155).

7 Apr 2010

OXiGENE regains compliance for continued listing on NASDAQ Global Market

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)

7 Apr 2010

Optimer Pharmaceuticals to present data from fidaxomicin Phase 3 studies at 20th ECCMID

Optimer Pharmaceuticals, Inc. announced that data from the fidaxomicin Phase 3 clinical studies will be presented at the 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.

7 Apr 2010

SRU Biosystems extends product line with the introduction of BIND SCANNER

SRU Biosystems today announced the extension of its product line of label-free instrumentation and biosensors with the introduction of its BIND® SCANNER for primary and stem cell applications. The BIND SCANNER is a first-of-its-kind, plate-based, label-free instrument capable of monitoring cellular responses at an individual cell resolution.

7 Apr 2010

Anthera Pharmaceuticals announces closing of underwriters' exercise of over-allotment option

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the closing of the underwriters' exercise of their over-allotment option to purchase an additional 604,492 shares of Anthera's common stock, at a price of $7.00 per share.

7 Apr 2010

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

Avastin approval to drive ovarian cancer drug market to $1.5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ovarian cancer drug market -- driven by the approval and rapid uptake of Roche/Genentech/Chugai's Avastin -- will more than triple from $449 million in 2008 to just under $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

7 Apr 2010

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), City of Hope Cancer Center (Duarte, Calif.) and the University of Chicago (Chicago, Ill).

7 Apr 2010

MicuRx Pharmaceuticals, Cumencor Pharmaceuticals, Pfizer collaborate to develop antibiotics for MDR-TB

MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc. today announced that the companies have entered a collaboration with Pfizer to discover novel therapeutic agents to treat multi-drug resistant tuberculosis.

7 Apr 2010

$13,000 per year AIDS drugs Reyataz: AHF calls upon BMS to lower price

AIDS Healthcare Foundation (AHF) is pressing New York-based drug firm Bristol-Myers Squibb (BMS) to lower the price of its key AIDS drug, Reyataz—currently priced at over $13,000 per year—for lifesaving, but financially hard-hit AIDS Drug Assistance Programs (ADAPs) nationwide.

7 Apr 2010

CancerGuide Diagnostics, Duke University form cancer research collaboration and licensing agreement

CancerGuide Diagnostics™, Inc. today announced that it has entered into a research collaboration and licensing agreement with Duke University to discover and develop tests to support individualized cancer treatment decisions.

7 Apr 2010

At home, congressional Dems face voters on health bill, Rep. Issa investigating 'deals'

Before Congress left town for the spring recess, Speaker Nancy Pelosi urged rank-and-file Democrats to return home and tout the benefits of the landmark health care bill, Politico reports.

7 Apr 2010

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc., today announced it will present three scientific posters featuring detailed Zenvia™ (dextromethorphan/quinidine) safety and efficacy data from the double-blind phase and the open label extension of the Phase III confirmatory STAR trial at the American Academy of Neurology Annual Meeting in Toronto, Canada, taking place April 10 - 17, 2010.

6 Apr 2010

Pharmaceuticals News and Research

Achaogen announces completion of $56M Series C round of financing

Illumina launches VeraCode ADME Core Panel

Gerresheimer AG sets up new sales office in Moscow

NNIT selects Verizon Business to manage global communications infrastructure for Novo Nordisk

Tigermed Consulting signs alliance agreement with ICON

TD2 to join GPEC at BayBio2010 to spur Arizona's bioscience industry

Senator Grassley issues warning about 'phanton pharmacies' while Tampa officials arrest pharmacists on fraud charges

Guidant imposed criminal penalty over $296M for withholding cardioverter defibrillator failure information

OXiGENE regains compliance for continued listing on NASDAQ Global Market

Optimer Pharmaceuticals to present data from fidaxomicin Phase 3 studies at 20th ECCMID

SRU Biosystems extends product line with the introduction of BIND SCANNER

Anthera Pharmaceuticals announces closing of underwriters' exercise of over-allotment option

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

Avastin approval to drive ovarian cancer drug market to $1.5 billion in 2018

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

MicuRx Pharmaceuticals, Cumencor Pharmaceuticals, Pfizer collaborate to develop antibiotics for MDR-TB

$13,000 per year AIDS drugs Reyataz: AHF calls upon BMS to lower price

CancerGuide Diagnostics, Duke University form cancer research collaboration and licensing agreement

At home, congressional Dems face voters on health bill, Rep. Issa investigating 'deals'

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence